Trovagene's urinary ctDNA assay outperforms tissue biopsy in clinical study
Trovagene announced that clinical data demonstrate that its urine-based Precision Cancer Monitoring℠ platform outperformed tissue biopsy for detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. April 17, 2015